All In Biotech

Drug Trial Radar · NCT00897104

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 933 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

933

Actual

Start

Aug 1995

Primary completion

May 1996

Study completion Sep 1996

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
May 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.

Conditions

  • Migraine Headache

Interventions

  • rizatriptan benzoate (MK0462)Drug

    single dose 5 mg rizatriptan p.o.

  • Comparator: sumatriptanDrug

    single dose 50 mg sumatriptan p.o.

  • Comparator: PlaceboDrug

    Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Relief at 2 Hours After TreatmentTime frame: 2 hours after treatment
  2. Time to Relief Within 2 Hours After TreatmentTime frame: within 2 hours after treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.